Meeting
2015 ASCO Annual Meeting
A phase II study of 5-fluorouracil (5-FU), ziv-aflibercept, and radiation for the preoperative and adjuvant treatment of patients (pts) with stage II/III rectal cancer.
Authors
Peter Acs
Florida Cancer Specialists/SCRI, Ft. Myers, FL
Peter Acs , Dana Shelton Thompson , Michael Brian Hemphill , David Wenk , Johanna C. Bendell , Andrew S. Kennedy
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer
Clinical Trial Registration Number
NCT01749956
Citation
J Clin Oncol 33, 2015 (suppl; abstr 3607)
DOI
10.1200/jco.2015.33.15_suppl.3607
Abstract #
3607
Poster Bd #
100
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Induction mFOLFOX6 with or without aflibercept followed by chemoradiation (CRT) and surgery in high risk rectal cancer: Phase II randomized, multicenter, openlabel trial—The GEMCAD RIA study.
First Author: Carlos Fernandez-Martos
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Total neoadjuvant therapy (TNT) for locally advanced rectal cancer (LARC): Real-world experience from a tertiary Asian cancer center.
First Author: Meng Wang
Poster
2018 ASCO Annual Meeting
RIA: Randomized phase II study comparing induction (I) mFOLFOX6 with or without aflibercept followed by chemoradiation (CRT) and total mesorectal excision (TME) in high risk-rectal cancer. GEMCAD 14-02 trial.
First Author: Carlos Fernandez-Martos
Poster
2021 Gastrointestinal Cancers Symposium
Neoadjuvant chemotherapy with modified FOLFOXIRI for locally advanced rectal cancer: A single center phase II trial.
First Author: Wen Zhang